Articles

The clinical relevance of calreticulin mutations in myeloproliferative neoplasms

BJH - volume 13, issue 8, december 2022

V. Havelange MD, PhD, S.N. Constantinescu MD, PhD

SUMMARY

Calreticulin mutations are driver mutations detected in around 20–25% of essential thrombocythemia and in 25–30% of primary myelofibrosis patients. The most recurrent mutations are type-1 (a deletion of 52 bp in the exon 9) and type-2 (an insertion of 5 bp in the exon 9). This review describes the distinct clinical features, prognosis and outcome of calreticulin mutated patients from JAK2V617F or MPL (thrombopoietin receptor) mutated patients. The subtypes of calreticulin mutations were also associated with distinct clinical characteristics. Several treatment guidelines were adapted for calreticulin-mutated patients. The mechanism by why the three driver mutations, which all activate JAK/STAT signalling pathway can trigger diseases with quite different features is still not known. The recent progress in the understanding of calreticulin mutation biology will allow the development of new target therapies with the hope to cure the disease in the next years.

(BELG J HEMATOL 2022;13(8):293–301)

Read more

P27 Role of FOXO1 mutations in the development of diffuse large B-cell lymphoma

BJH - 2018, issue Abstract Book BHS, february 2018

E. Bollaert , A. Velghe , G. Dachy , V. Havelange MD, PhD, J.B. Demoulin

Read more

P16 Preleukemic phase of chronic myeloid leukemia presenting with an isolated peripheral basocytosis

BJH - 2018, issue Abstract Book BHS, february 2018

F. Dall’Armellina , Y. Berners , L. Maindiaux , A. Capes , J-P. Defour PhD, P. Saussoy MD, PhD, V. Havelange MD, PhD, M-C. Vekemans MD, PhD

Read more

P38 Coexistence of inversion (16) et Bcr-Abl rearrangement in acute myeloid leulemia: a clinical description

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Devreux , G. Di Prinzio , S. Bailly MD, S. Lefebvre , G. Verstraete , K. van Renterghem , A. Charlot , P. Saussoy MD, PhD, J-P. Defour PhD, N. Straetmans MD, PhD, X. Poiré MD, PhD, L. Michaux MD, PhD, M-C. Vekemans MD, PhD, V. Havelange MD, PhD

Read more

P79 Atypical bone pain after allogeneic bone marrow transplantation for myelofibrosis

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Verstraete , S. Lefevre , S. Bailly MD, G. Di Prinzio , J. Devreux , J-P. Defour PhD, P. D’Abadie , P. Van Eeckhout , F. Kino , C. Goemare , N. Lepage , L. Michaux MD, PhD, V. Havelange MD, PhD, E. Van den Neste MD, PhD, C. Lambert MD, L. Knoops MD, PhD, M-C. Vekemans MD, PhD, X. Poiré MD, PhD

Read more

PP31 Roles of microRNAs in myeloid malignancies driven by activated tyrosine kinases

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Claus , A. Essaghir , P. Saussoy MD, PhD, L. Michaux MD, PhD, J.B. Demoulin , V. Havelange MD, PhD

Read more

P3.03 Anemia, thrombocytopenia and radiculitis in the setting of allogeneic stem cell transplantation

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Amat , T. Tamakloe , N. Meité , V. Havelange MD, PhD, M-C. Vekemans MD, PhD, C. Lambert MD, E. Van den Neste MD, PhD, X. Poiré MD, PhD

Read more
X